OOIR: Observatory of International Research

Papers

(The H4-Index of BMC Cancer is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Lnc-SELPLG-2:1 enhanced osteosarcoma oncogenesis via hsa-miR-10a-5p and the BTRC cascade	253
Evaluating the prognostic performance of a polygenic risk score for breast cancer risk stratification	143
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer	119
Chemotherapy dose per kilogram lean body mass increased dose-limiting toxicity event in male head and neck cancer with taxane and platinum-based induction therapy	116
Low-grade inflammation in survivors of childhood cancer and testicular cancer and its association with hypogonadism and metabolic risk factors	110
Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer	90
The gene expression profile and cell of origin of canine peripheral T-cell lymphoma	89
Changing patterns of nasopharyngeal carcinoma incidence in Hong Kong: a 30-year analysis and future projections	86
Effects of neoadjuvant radiochemotherapy for anorectal function in locally advanced rectal cancer patients: a study protocol for a prospective, observational, controlled, multicentre study	80
Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma—randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol	76
Development and psychometric properties of Health-Promoting Lifestyle Scale in Colorectal Cancer Survivors (HPLS-CRCS): a mixed-method study	71
ESR1 PvuII polymorphism: from risk factor to prognostic and predictive factor of the success of primary systemic therapy in advanced breast cancer	69
Single-copy Snail upregulation causes partial epithelial-mesenchymal transition in colon cancer cells	66
Network Evolution Model-based prediction of tumor mutation burden from radiomic-clinical features in endometrial cancers	66
Adult breast, lung, pancreatic, upper and lower gastrointestinal cancer patients with hospitalized venous thromboembolism in the national French hospital discharge database	65
Integrated pancancer analysis reveals the oncogene characteristics and prognostic value of DIP2B in breast cancer	61
Association of oxaliplatin-containing adjuvant duration with post-treatment fall-related injury and fracture in patients with stage III colon cancer: a population-based retrospective cohort study	60
Rapid and label-free detection of gastrointestinal stromal tumor via a combination of two-photon microscopy and imaging analysis	60
Exploring optimal administration timing of pegylated recombinant human granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in early breast cancer treated with pharmorubicin and	58
Results from a real-world study: a novel glycosyltransferase risk score for prognosis, tumor microenvironment phenotypes and immunotherapy in bladder cancer	58
Predicting biochemical-recurrence-free survival using a three-metabolic-gene risk score model in prostate cancer patients	55
The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma	54
Image-guided navigation for locally advanced primary and locally recurrent rectal cancer: evaluation of its early cost-effectiveness	52
Deep learning based on intratumoral heterogeneity predicts histopathologic grade of hepatocellular carcinoma	52
Increased use of diagnostic CT imaging increases the detection of stage IA lung cancer: pathways and patient characteristics	49

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer	48
Favorable locoregional control in clinically node-negative hormone-receptor positive breast cancer with low 21-gene recurrence scores: a single-institution study with 10-year follow-up	48
NTRK fusion promotes tumor migration and invasion through epithelial–mesenchymal transition and closely interacts with ECM1 and NOVA1	48
Correlation between overall survival and quality of life in colon cancer patients with chemotherapy	48
Realizing the promise of machine learning in precision oncology: expert perspectives on opportunities and challenges	47
Gross recurrent laryngeal nerve invasion by extranodal extension in thyroid carcinoma	47
The impact of curative cancer treatment on sexual health – clinical results from the EORTC QLQ-SH22 validation study	46
Unraveling the causal links and novel molecular classification of Crohn’s disease in breast Cancer: a two-sample mendelian randomization and transcriptome analysis with prognostic modeling	46
Integrated analysis of single-cell and bulk transcriptomics reveals cellular subtypes and molecular features associated with osteosarcoma prognosis	46
Prospective clinical evidence from over 1,000 pan-cancer patients: a complement to fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting	46
Long noncoding RNA TMPO-AS1 accelerates glycolysis by regulating the miR-1270/PKM2 axis in colorectal cancer	46
Neoadjuvant immune checkpoint inhibitor reduced recurrence in operable NSCLC patients with pathological complete response: a retrospective analysis	45
The mortality rate of people with cancer judged to have a limited life expectancy by physicians performing work disability assessments in the Netherlands: a retrospective cohort study	44
Azacytidine treatment affects the methylation pattern of genomic and cell-free DNA in uveal melanoma cell lines	44
Immunohistochemical analysis of Tn antigen expression in colorectal adenocarcinoma and precursor lesions	43
Efficacy and safety of PD-1/PD-L1 inhibitors in patients with Merkel Cell Carcinoma: a systematic review and Meta-analysis	43
Analysis of characteristics of peripheral blood lymphocytes in endometrial carcinoma: a single-center study based on five-year clinical data	43
Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer,	43